CanSino candidate, Ad5-nCOV, which was tested in 508 subjects, is one of a handful of vaccines that have shown some promise in early human testing prior to much larger trials to demonstrate efficacy.
Others also gearing up for such pivotal vaccine trials include Moderna Inc , BioNTech SE <22UAy.F> in partnership with Pfizer Inc .Data from a combined early/midstage trial of a vaccine candidate being developed by researchers at the University of Oxford and AstraZeneca was also released on Monday.